Cardiff Oncology Inc. (NASDAQ: CRDF)
$2.62
+0.1050 ( +4.18% ) 326.0K
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Market Data
Open
$2.62
Previous close
$2.51
Volume
326.0K
Market cap
$116.76M
Day range
$2.53 - $2.65
52 week range
$0.94 - $6.42
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Nov 14, 2023 |
10-q | Quarterly Reports | 48 | Nov 02, 2023 |
8-k | 8K-related | 26 | Nov 02, 2023 |
8-k | 8K-related | 42 | Sep 26, 2023 |
8-k | 8K-related | 16 | Aug 09, 2023 |
10-q | Quarterly Reports | 56 | Aug 09, 2023 |
8-k | 8K-related | 63 | Aug 07, 2023 |
8-k | 8K-related | 15 | Jul 24, 2023 |